ANAB — AnaptysBio Income Statement
0.000.00%
Last trade - 00:00
- $607.79m
- $216.89m
- $17.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8 | 75 | 63.2 | 10.3 | 17.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 115 | 98.9 | 120 | 125 | 182 |
Operating Profit | -107 | -23.9 | -56.8 | -115 | -164 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -97.5 | -19.9 | -57.8 | -129 | -164 |
Provision for Income Taxes | |||||
Net Income After Taxes | -97.3 | -19.9 | -57.8 | -129 | -164 |
Net Income Before Extraordinary Items | |||||
Net Income | -97.3 | -19.9 | -57.8 | -129 | -164 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -97.3 | -19.9 | -57.8 | -129 | -164 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.6 | -0.73 | -2.11 | -4.57 | -6.08 |